We are continuing to face significant capacity challenges and will be delaying the development of tralokinumab for treating moderate to severe atopic dermatitis [ID3734]. This topic will now be considered as part of a multiple technology appraisal [ID3960]. We anticipate that it will be considered by the technology appraisal committee in March 2022.
| Status | Schedule affected by COVID-19 |
| Decision | Selected |
| Process | TA |
| ID number | 3734 |
Project Team
| Project lead | Shonagh D'Sylva |
Email enquiries
- If you have any queries please email TAteam2@nice.org.uk
| External Assessment Group | BMJ Technology Assessment Group (BMJ-TAG), BMJ |
Stakeholders
| Companies sponsors | Leo Pharma (tralokinumab) |
| Others | Department of Health and Social Care |
| NHS England | |
| Welsh Government | |
| Patient carer groups | National Eczema Society |
| Professional groups | British Association of Dermatologists |
| Royal College of Physicians | |
| Associated public health groups | None |
| Comparator companies | GlaxoSmithKline (alitretion) |
| Novartis Pharmaceuticals (ciclosporin, mycophenolate mofetil) | |
| Pfizer (methotrexate) | |
| Sanofi (dupilumab) | |
| General commentators | All Wales Therapeutics and Toxicology Centre |
| British National Formulary | |
| Department of Health, Social Services and Public Safety for Northern Ireland | |
| Healthcare Improvement Scotland | |
| Medicines and Healthcare products Regulatory Agency | |
| Scottish Medicines Consortium | |
| Welsh Health Specialised Services Committee | |
| Relevant research groups | None |
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 05 August 2021 | Due to significant capacity challenges NICE has paused the development of the Single Technology Appraisals for [ID3768] abrocitinib for treating moderate to severe atopic dermatitis in people aged 12 and over, [ID3733] Upadacitinib for treating moderate to severe atopic dermatitis in people aged 12 and over and [ID3734] Tralokinumab for treating moderate to severe atopic dermatitis. All 3 topics will be appraised together as a Multiple Technology Appraisal under [ID3960]. |
| 04 August 2021 | Schedule affected by COVID-19. We are continuing to face significant capacity challenges and will be delaying the development of tralokinumab for treating moderate to severe atopic dermatitis [ID3734]. This topic will now be considered as part of a multiple technology appraisal [ID3960]. We anticipate that it will be considered by the technology appraisal committee in March 2022. |
| 09 February 2021 | Invitation to participate |
| 05 October 2020 | The Department for Health and Social Care has asked NICE to conduct an appraisal of tralokinumab for treating moderate to severe atopic dermatitis. Please note that following on from a request received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in early February 2021. These timings are based on a request from the company to reschedule the initial date set by NICE, in order to facilitate a suitably comprehensive submission. |
| 05 October 2020 | In progress. Topic is in progress |
| 22 July 2020 - 19 August 2020 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
For further information on our processes and methods, please see our CHTE processes and methods manual